Document is current
Any future updates will be listed below
-
Authors
Nepali, Prerna R. https://orcid.org/0000-0002-7472-1041
Gonzalez-Kozlova, Edgar https://orcid.org/0000-0002-6948-0626
Anegondi, Maitri https://orcid.org/0009-0000-7312-8898
Dogra, Navneet https://orcid.org/0000-0002-4602-3991
Archer, Maddison
Chakraborty, Goutam https://orcid.org/0000-0002-4387-2621
Tewari, Ashutosh K.
Hopkins, Benjamin D. https://orcid.org/0000-0002-7970-6430
Kyprianou, Natasha https://orcid.org/0000-0002-8713-3599
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA232574)
U.S. Department of Health & Human Services | National Institutes of Health (U24CA224319)
U.S. Department of Health & Human Services | National Institutes of Health (R21 AGO78848)
U.S. Department of Health & Human Services | National Institutes of Health (R01 R01CA274967)
U.S. Department of Defense (W81XWH-19-1- 0470)
Prostate Cancer Foundation (Young Investigator Award)
- License Information
-
More Information
Article History
Received: 1 May 2025
Revised: 12 September 2025
Accepted: 6 October 2025
First Online: 22 November 2025
Competing interests
: NK serves on the advisory board for Onconox Inc. GC has served as a scientific consultant for GuidePoint and GLG and received consultation fees. AKT has served as a site-PI on sponsored clinical trials from Kite Pharma Inc., Lumicell Inc., Dendron Pharmaceuticals, LLC., Oncovir Inc., Blue Earth Diagnostics Ltd., RhoVac ApS., Bayer HealthCare Pharmaceuticals Inc. and Janssen Research and Development, LLC. The other authors declare no competing interests.
: All experiments have been performed in accordance with the relevant guidelines and regulations. This research article does not include any studies with live vertebrates or humans.
